03860 EPS HEALTH TECH
- 1.000
- +0.050+5.26%
EPS HEALTH TECH News
EPS Creative Health Technology Completes Issue of HK$22 Million Worth of Shares
EPS Creative Health Technology Group (HKG:3860) completed the issue of about 22.2 million shares to two subscribers for a total consideration of HK$22 million, according to a Monday filing on the Hong
EPS Chuangjian Technology (03860.HK) completed allotment of a total of 22.18 million shares
Gelonghui, April 22 | EPS Chuangjian Technology (03860.HK) announced that on April 22, 2024, the prerequisites for subscription agreement A and subscription agreement B have all been met and implemented. On April 22, 2024, (i) 10,080,645 subscription shares have been allocated and issued to Subscriber A at a subscription price of HK$0.992 per subscription share; and (ii) 12,096,774 subscription shares have been allocated and issued to Subscriber B at a subscription price of HK$0.992 per subscribed share.
EPS Chuangjian Technology (03860.HK) plans to allocate a total of 22.18 million shares to raise approximately HK$21.8 million
Gelonghui, April 9 | EPS Chuangjian Technology (03860.HK) announced that on April 9, 2024, the company (i) entered into a subscription agreement A with subscriber A KIRABOSHI CONSULTING CO., LTD. According to this, the company has agreed to allocate and issue and subscriber A has already agreed to subscribe for 1.08 million new shares at a subscription price of HK$0.992 per share; and (ii) entered into a subscription agreement B with the subscriber B OHMI LLC (existing contract company Omi), according to the company's terms Subscribers who agree to distribute and distribute
EPS Chuangjian Technology (03860): Yasuhiko Taniguchi will be appointed as an independent non-executive director
EPS Chuangjian Technology (03860) issued an announcement. Junichi Taguchi has proposed to resign as an independent non-executive director in order to specialize...
EPS Chuangjian Technology (03860) signed a reward agreement with Chen Yongqi, and Chen Yongqi promised that it would enable Apparel Group to achieve certain performance goals in terms of profit and revenue during the performance period
Zhitong Finance App Xun, EPS Chuangjian Technology (03860) issued an announcement. On March 6, 2024 (after the trading period), the company and Chen...
EPS Creative Health Technology Acquires Japan's Biotube
EPS Creative Health Technology Group (HKG:3860) said unit EPS Innovative Medicine (Japan) has purchased Biotube's entire stock, from three vendors, for about HK$31.8 million and has exchanged converti
EPS Chuangjian Technology (03860) completed the acquisition of approximately 47.3% of Biotube Co., Ltd.
EPS Chuangjian Technology (03860) issued an announcement. On November 29, 2023, the company's wholly-owned subsidiary...
EPS HEALTH TECH: INTERIM REPORT 2023/2024
EPS Creative Health Technology Unit Signs Deal for Clinical Trial Services
EPS Creative Health Technology Group's (HKG:3860) unit, EPS Medical Consultancy (Japan), agreed to receive clinical trial services from EPS and EP Mediate, entities connected to the healthcare company
Selected Announcements | Oriental Selection: Yu Minhong appointed as CEO and Sun Dongxu removed as CEO; Shang Tang: Founder Tang Xiaoou passed away due to illness
China Coal Energy: Commercial coal sales in November were 23.16 million tons, up 21.7% year on year; CRRC: CRRC Capital plans 900 million yuan to participate in the Huayi Hi-Tech Traffic Control Industry Chain Investment Fund partnership; Air China: November passenger turnover rose 348.6% year on year, down 10.7% month on month.
EPS Chuangjian Technology (03860.HK) signed a CRO service framework agreement
Gelonghui December 15 | EPS Chuangjian Technology (03860.HK) announced that on December 15, 2023, EPSMC (a subsidiary of the company) signed a CRO service framework agreement with EPS Corporation and EP Media. According to this, EPS Corporation and EPMediate have agreed to provide CRO services to EPSMC within the three fiscal years ending March 31, 2026.
EPS Creative Health Arm to Buy 47% of Japanese Firm Biotube
EPS Creative Health Technology Group (HKG:3860) said subsidiary EPS Innovative Medicine (Japan) will pick a roughly 47.3% stake in Japanese firm Biotube, from three vendors. The cash and stock deal wi
EPS Creative Health Technology Trims Loss in Fiscal H1
EPS Creative Health Technology Group (HKG:3860) trimmed its loss attributable to owners of HK$5.2 million, or HK$0.0105 per share, for the fiscal first half from HK$18.9 million, or HK$0.0378 per shar
EPS Chuangjian Technology (03860) plans to acquire approximately 47.3% of Biotube Co., Ltd.'s shares for 612 million yen
EPS Chuangjian Technology (03860) issued an announcement. On November 29, 2023, the company's wholly-owned subsidiary...
EPS Chuangjian Technology (03860.HK): Interim net loss of HK$5.235,000
Gelonghui November 29丨EPS Chuangjian Technology (03860.HK) announced that for the six months ended September 30, 2023, it had achieved a profit of HK$358 million, an increase of 38.5% over the previous year; the company owners accounted for a loss of HK$5.23,000; the company owners accounted for a loss of HK$18.923 million in the same period last year; and a basic loss of HK$1.05 per share.
EPS HEALTH TECH: INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
EPS Creative Health to Shrink April-September Loss
EPS Creative Health Technology Group (HKG:3860) expects a loss of approximately HK$4 million for the six months ended Sept. 30, down from HK$20 million during the year-ago period. The knitwear apparel
EPS Chuangjian Technology (03860) Fa Profit Alert expects a loss of about HK$4 million in the medium term
EPS Chuangjian Technology (03860) announced that the group expects to lose money for 6 months ending September 30, 2023...
EPS HEALTH TECH: REDUCTION IN LOSS FOR THE SIX MONTHS ENDED 30 SEPTEMBER 2023
EPS Chuangjian Technology (03860.HK) will hold a board meeting on November 29 to approve the interim results
Gelonghui November 13丨EPS Chuangjian Technology (03860.HK) announced that the board of directors will hold a board meeting on November 29, 2023 to (a) discuss and approve the unaudited interim results of the company and its subsidiaries for the six months ended September 30, 2023; and (b) consider the payment of interim dividends (if any).
Analysis
Price Target
No Data
